Stock PMCB PHARMACYTE BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials PharmaCyte Biotech, Inc.

Equities

PMCB

US71715X2036

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.11 USD -0.47% Intraday chart for PharmaCyte Biotech, Inc. -0.47% -2.31%
Mar. 18 PharmaCyte Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
2023 PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI

Valuation

Fiscal Period: April 2018 2019 2020 2021 2022 2023
Capitalization 1 54.72 46.2 36.3 42.25 48.28 50.93
Enterprise Value (EV) 1 53.66 45.69 35.59 40.1 -37.12 -17.11
P/E ratio -5.4 x -11.1 x -8.68 x -10.8 x -8.53 x -13.2 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - - - - - -
EV / FCF -20.5 x -33.7 x -34.6 x -20.3 x 14.2 x 4.86 x
FCF Yield -4.87% -2.97% -2.89% -4.91% 7.07% 20.6%
Price to Book 9.49 x 9.65 x 7.89 x 6.33 x 0.54 x 0.67 x
Nbr of stocks (in thousands) 676 751 988 1,590 20,721 17,443
Reference price 2 81.00 61.50 36.75 26.57 2.330 2.920
Announcement Date 7/20/18 8/13/19 8/13/20 8/10/21 7/28/22 7/31/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: April 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA - - - - - -
EBIT 1 -6.981 -4.101 -3.826 -3.623 -4.392 -6.455
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -6.829 -4.067 -3.827 -3.551 -4.239 -4.316
Net income 1 -6.829 -4.067 -3.827 -3.551 -4.239 -4.316
Net margin - - - - - -
EPS 2 -15.00 -5.545 -4.234 -2.452 -0.2731 -0.2215
Free Cash Flow 1 -2.614 -1.356 -1.029 -1.971 -2.623 -3.518
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 7/20/18 8/13/19 8/13/20 8/10/21 7/28/22 7/31/23
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: April 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales 1 - - - -
EBITDA - - - -
EBIT 1 -1.005 -0.8561 -1.508 -1.681
Operating Margin - - - -
Earnings before Tax (EBT) - - - -
Net income - - - -
Net margin - - - -
EPS - - - -
Dividend per Share - - - -
Announcement Date 12/14/21 3/15/22 7/28/22 9/14/22
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: April 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1.06 0.52 0.71 2.15 85.4 68
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -2.61 -1.36 -1.03 -1.97 -2.62 -3.52
ROE (net income / shareholders' equity) -98.6% -75.3% -75.6% -60.4% -8.78% -5.31%
ROA (Net income/ Total Assets) -57.9% -42% -40% -33.4% -5.6% -4.92%
Assets 1 11.8 9.677 9.56 10.64 75.69 87.66
Book Value Per Share 2 8.540 6.370 4.660 4.200 4.340 4.330
Cash Flow per Share 2 1.570 0.6500 0.8200 1.380 4.120 4.050
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 7/20/18 8/13/19 8/13/20 8/10/21 7/28/22 7/31/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PHARMACYTE BIOTECH, INC. Stock PharmaCyte Biotech, Inc.
-2.31% 17.84M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PMCB Stock
  4. Financials PharmaCyte Biotech, Inc.